ArticleThe Journal of pharmacology and experimental therapeutics2015

Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation.

Jingjing Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.